⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TAK News
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda annonce les premiers résultats positifs d’un essai clinique pivot de phase 2/3 sur le TAK-881 dans le traitement des déficits immunitaires primaires (DIP)
businesswire.com
TAK
Takeda gibt positive Topline-Ergebnisse einer entscheidenden klinischen Phase-2/3-Studie mit TAK-881 bei primären Immundefekten (PID) bekannt
businesswire.com
TAK
Samenvatting: Takeda maakt positieve voorlopige resultaten bekend van een cruciaal fase 2/3-klinisch onderzoek naar TAK-881 bij primaire immuundeficiëntie (PID)
businesswire.com
TAK
Takeda宣布針對原發性免疫缺陷病（PID）開發的新藥TAK-881在二/三期臨床試驗中取得正面頂線結果
businesswire.com
TAK
Takeda宣布其用于治疗原发性免疫缺陷病（PID）的TAK-881关键性Ⅱ/Ⅲ期临床试验取得积极顶线结果
businesswire.com
TAK
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight
globenewswire.com
NVS
VRTX
BIIB
VTRS
AZN
IONS
TAK
ARWR
WLDN
Global AAV Vector Manufacturing Market Gearing Up for Outstanding Expansion at a CAGR of ~22% by 2034 | DelveInsight
globenewswire.com
PFE
CSL
AMTX
JNJ
SLDB
QURE
TMO
CRL
MRK
TAK
Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight
globenewswire.com
TSEM
TAK
MRK
IONS
SLN
INCY
JNJ
VNDA
Global Lung Cancer Therapeutics Market to Reach USD 142.3 Billion as Precision Medicine and Immunotherapy Redefine Oncology Care | Future Market Insights
prnewswire.com
AZN
MRK
BMY
PFE
LLY
NVS
TAK
AMGN
Paratus Appoints Alicia Secor as President and Chief Executive Officer; Expands Leadership Team to Support Next Phase of Growth
globenewswire.com
ZNTL
CRBU
AZN
PFE
TLRY
CATX
SYPR
SGBX
TMDX
LMT
TKO
TAK
SNY
EXAS